EP3564362A1 - Skeletal muscle cells and method for inducing same - Google Patents
Skeletal muscle cells and method for inducing same Download PDFInfo
- Publication number
- EP3564362A1 EP3564362A1 EP17888624.8A EP17888624A EP3564362A1 EP 3564362 A1 EP3564362 A1 EP 3564362A1 EP 17888624 A EP17888624 A EP 17888624A EP 3564362 A1 EP3564362 A1 EP 3564362A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- gene
- cells
- skeletal muscle
- cell
- myc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002363 skeletal muscle cell Anatomy 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title claims abstract description 49
- 230000001939 inductive effect Effects 0.000 title claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 135
- 230000014509 gene expression Effects 0.000 claims abstract description 62
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 37
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 claims abstract description 26
- 108091057508 Myc family Proteins 0.000 claims abstract description 22
- 241000124008 Mammalia Species 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 141
- 241000282414 Homo sapiens Species 0.000 claims description 41
- 210000002950 fibroblast Anatomy 0.000 claims description 36
- 238000002054 transplantation Methods 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 108700024542 myc Genes Proteins 0.000 claims description 24
- 210000002027 skeletal muscle Anatomy 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 9
- 230000007547 defect Effects 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 3
- 239000013598 vector Substances 0.000 description 51
- 239000002609 medium Substances 0.000 description 36
- 210000003098 myoblast Anatomy 0.000 description 32
- 241001430294 unidentified retrovirus Species 0.000 description 32
- 239000000047 product Substances 0.000 description 29
- 108020004999 messenger RNA Proteins 0.000 description 26
- 108010056785 Myogenin Proteins 0.000 description 21
- 230000004069 differentiation Effects 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 17
- 230000008672 reprogramming Effects 0.000 description 15
- 210000004940 nucleus Anatomy 0.000 description 14
- 210000003205 muscle Anatomy 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 12
- 230000037311 normal skin Effects 0.000 description 12
- 238000003753 real-time PCR Methods 0.000 description 12
- 210000001626 skin fibroblast Anatomy 0.000 description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 238000012546 transfer Methods 0.000 description 12
- 101150115442 CKM gene Proteins 0.000 description 11
- 102100032970 Myogenin Human genes 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000012758 nuclear staining Methods 0.000 description 9
- 108010085238 Actins Proteins 0.000 description 8
- 108010044052 Desmin Proteins 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- 102100036912 Desmin Human genes 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 210000005045 desmin Anatomy 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 101000585703 Homo sapiens Protein L-Myc Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000003125 immunofluorescent labeling Methods 0.000 description 6
- 210000001087 myotubule Anatomy 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101100239683 Homo sapiens MYOD1 gene Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000005088 multinucleated cell Anatomy 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108010069091 Dystrophin Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 4
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 101150015424 dmd gene Proteins 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 102000001039 Dystrophin Human genes 0.000 description 3
- 102100024108 Dystrophin Human genes 0.000 description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
- 201000002481 Myositis Diseases 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- QAPAJIZPZGWAND-UHFFFAOYSA-N XMD8-92 Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OCC)=CC=1N1CCC(O)CC1 QAPAJIZPZGWAND-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- -1 CKM Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000006562 Glycogen Storage Disease Type VII Diseases 0.000 description 2
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 2
- 208000032000 Glycogen storage disease due to muscle glycogen phosphorylase deficiency Diseases 0.000 description 2
- 208000031926 Glycogen storage disease due to muscle phosphofructokinase deficiency Diseases 0.000 description 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 2
- 206010018462 Glycogen storage disease type V Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229930185229 antidesmin Natural products 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 230000037020 contractile activity Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 201000004502 glycogen storage disease II Diseases 0.000 description 2
- 201000004534 glycogen storage disease V Diseases 0.000 description 2
- 201000009339 glycogen storage disease VII Diseases 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- IKEOZQLIVHGQLJ-UHFFFAOYSA-M mitoTracker Red Chemical compound [Cl-].C1=CC(CCl)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 IKEOZQLIVHGQLJ-UHFFFAOYSA-M 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000003699 striated muscle Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 206010045458 umbilical hernia Diseases 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- 206010002120 Anal atresia Diseases 0.000 description 1
- 208000009115 Anorectal Malformations Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150074276 CIDEA gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000032589 Diaphragmatic Congenital Hernias Diseases 0.000 description 1
- 206010066871 Disuse syndrome Diseases 0.000 description 1
- 206010051025 Eagle Barrett syndrome Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 206010015677 Exomphalos Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000006442 Gastroschisis Diseases 0.000 description 1
- 208000032008 Glycogen storage disease due to glycogen debranching enzyme deficiency Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 101100257362 Homo sapiens SOX2 gene Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000029836 Inguinal Hernia Diseases 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 102000042106 MEF2 family Human genes 0.000 description 1
- 108091077694 MEF2 family Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010068836 Metabolic myopathy Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 108010054849 MyoD1 myogenic differentiation protein Proteins 0.000 description 1
- 102100038380 Myogenic factor 5 Human genes 0.000 description 1
- 101710099061 Myogenic factor 5 Proteins 0.000 description 1
- 102100038379 Myogenic factor 6 Human genes 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 102100038317 Myosin-3 Human genes 0.000 description 1
- 101710204040 Myosin-3 Proteins 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 201000002048 Prune Belly Syndrome Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101150086605 Runx2 gene Proteins 0.000 description 1
- 101150106167 SOX9 gene Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101150022052 UCP1 gene Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000001593 brown adipocyte Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008668 cellular reprogramming Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 201000005890 congenital diaphragmatic hernia Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000001968 dental pulp cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001648 gingival epithelial cell Anatomy 0.000 description 1
- 201000004543 glycogen storage disease III Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057030 human MYCL Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000002358 imperforate anus Diseases 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 101150042523 myod gene Proteins 0.000 description 1
- 108010084677 myogenic factor 6 Proteins 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000003508 omphalocele Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention mainly relates to a skeletal muscle cell and an induction method thereof. More particularly, it relates to a method for inducing a skeletal muscle cell by direct reprogramming.
- Muscle is an essential tissue for animal exercise and is composed of filamentous multinucleated cells having contractile activity. In induction of differentiation of skeletal muscle, mononuclear myoblasts are differentiated and fused to form multinucleated muscle cells. It is known that differentiation induction of skeletal muscle is controlled by transcription factors such as MyoD family and MEF2 family.
- muscles can be regenerated and transplanted in diseases such as congenital abnormalities of muscles such as diaphragmatic agenesis and the like, hereditary diseases of muscles such as muscular dystrophy and the like, muscle defects caused by severe trauma or surgical treatment, and the like, it may become an effective new regenerative medicine.
- myoblast-like cells can be induced by introducing a skeletal muscle-specific transcription factor, a gene of the MyoD family, into mouse fibroblasts.
- a gene of the MyoD family a gene of the MyoD family
- myoblasts cannot be induced to the same extent as mouse.
- non-patent document 1 Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell. 1987 Dec 24; 51(6):987-1000 .
- the present invention aims to provide a method for inducing skeletal muscle cells that can be applied to a treatment of a disease accompanying muscle defect and the like.
- skeletal muscle cells can be obtained directly by introducing MyoD gene and L-myc gene in combination into somatic cells of a mammal (direct reprogramming) without conversion into pluripotent stem cells, such as ES cells and iPS cells.
- pluripotent stem cells such as ES cells and iPS cells.
- the present invention has been completed by performing further studies based on such findings.
- the present invention encompasses the following invention.
- a method for inducing (generating) a skeletal muscle cell comprising a step of introducing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into a somatic cell of a mammal.
- a transplantation material comprising a cell obtained by the method of any one of items 1 to 4 or the skeletal muscle cell of item 4 for the treatment of a disease based on defect, deficiency or loss of function of skeletal muscle.
- a composition for inducing (generating) a skeletal muscle cell comprising MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof.
- skeletal muscle cells can be prepared from somatic cells by direct reprogramming in a short period of time.
- the skeletal muscle cells can be induced easily from somatic cells of a person who undergoes transplantation. Accordingly, when skeletal muscle cells are transplanted, problems, such as an immunological rejection response, do not occur.
- skeletal muscle cells can be induced directly from somatic cells without conversion into iPS cells or ES cells, and hence problems due to pluripotent stem cells, such as carcinogenesis, can be avoided.
- the present invention relates to a method for inducing a skeletal muscle cell by converting a mammalian differentiated somatic cell into a skeletal muscle cell.
- the term "convert” herein means changing a somatic cell into a target skeletal muscle cell.
- One preferred embodiment of the method of the present invention provides a method of converting a somatic cell into a skeletal muscle cell without reprogramming of cells, such as production of iPS cells, which is also called “direct reprogramming" or "direct conversion.”
- Induction into a skeletal muscle cell can be performed either in vitro or in vivo.
- myoblasts fuse into multinucleated myotube cells and mature into myofibers.
- Normal skeletal muscle tissue contains muscle satellite cells capable of functioning as stem cells.
- myoblast, muscle satellite cell, myotube cell, myotube, myofiber, mature myofiber and the like are collectively referred to as skeletal muscle cell or muscle cell.
- Skeletal muscle refers to muscles other than cardiac muscle and smooth muscle among animal muscles. Of the striated muscle and smooth muscle, skeletal muscle belongs to the striated muscle. Skeletal muscle cells are multinucleated cells, and muscle fiber is produced from many myoblasts.
- Skeletal muscle cell is derived from mesenchymal stem cell. In differentiation in vivo, mesenchymal stem cell is differentiated into myoblast and many myoblasts are fused to form myotube cell.
- skeletal muscle cell can be evaluated based on gene expression and protein expression of skeletal muscle-specific markers such as Myogenin, creatine kinase muscle (CKM), Myosin heavy chain 3 (MHC 3) and the like, and morphological features such as formation of multinucleus and muscle fibers, functions such as contractile activity and the like.
- CKM creatine kinase muscle
- MHC 3 Myosin heavy chain 3
- somatic cells derived from mammals can be used.
- somatic cells autologous cells
- somatic cells derived from a test subject who undergoes transplantation
- skeletal muscle cells prepared in advance from somatic cells of other persons or other animals may be used for, for example, transplantation for muscle deficiency or the like.
- skeletal muscle cells can be prepared from somatic cells of another person or another animal prepared in advance, and used for transplantation. That is, a skeletal muscle cell bank can be prepared in advance, and used for transplantation.
- MHC typing can be carried out in advance. Further, cell properties and tumorigenicity of skeletal muscle cells can be confirmed in advance.
- mammals include mice, rats, hamsters, humans, dogs, cats, monkeys, rabbits, cows, horses, pigs, and the like, particularly humans.
- the somatic cell as the subject of the method of the present invention (direct reprogramming) is not particularly limited.
- somatic cell a somatic cell that can be easily collected from a living body can be used.
- examples thereof include fibroblasts, keratinocytes, oral mucosal epithelial cells, nasal mucosal epithelial cells, respiratory mucosal epithelial cells, gastric mucosal epithelial cells, intestinal mucosal epithelial cells, vascular endothelial cells, smooth muscle cells, adipocytes, gingival cells (gingival fibroblasts and gingival epithelial cells), dental pulp cells, periodontal ligament cells, bone marrow cells, bone marrow-derived interstitial cells, leukocytes, lymphocytes, conjunctival epithelial cells, and osteoclasts, preferably fibroblasts, keratinocytes, oral mucosal epithelial cells, gingival cells, leukocytes, and lymphocytes.
- the above-mentioned cell collected from a living body is preferably used.
- MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof are introduced into somatic cells.
- the "expression product” is, for example, mRNA or protein of MyoD family gene or L-myc gene.
- micro RNA, siRNA, shRNA and DNA expressing them can also be used in addition to the MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof.
- various proteins can also be used in combination. From the viewpoint of efficiency with which skeletal muscle cells can be obtained and from the viewpoint of convenience, it is preferable to use two genes of MyoD family gene and Myc family gene, for example, two genes alone of MyoD1 gene and L-myc gene.
- MyoD family gene is a group of genes encoding bHLH (basic helix loop helix) type transcription factors involved in the control of differentiation of muscle.
- Examples of the MyoD family gene include MyoD1, Myf5, myogenin and MRF4.
- the MyoD family gene is preferably MyoD1 gene.
- Myc family gene also encodes bHLH (basic helix loop helix) type transcription factors.
- Examples of the Myc family gene include c-myc, N-myc and L-Myc.
- the Myc family gene is preferably L-Myc.
- genes are highly conserved in vertebrates. In this specification, they refer to genes including homologues, unless a specific animal name is described. The genes further include genes having functions equivalent to those of wild-type gene products, even when the genes include mutations including polymorphisms.
- cDNA base sequences of human (Homo sapiens) MyoD1 gene and L-myc gene, and amino acid sequences of proteins encoded by these sequences have been registered at GenBank provided by the National Center for Biotechnology Information (NCBI), under the following accession numbers (it should be understood that when multiple revisions have been registered, each number refers to the latest revision):
- the method of the present invention can be performed according to a known direct reprogramming method, except that specific genes are selected.
- the method can be performed according to the method described in any one of the following documents:
- the object gene into one or plural expression vectors and introduce the expression vector into target somatic cells to express the gene in the cells.
- a method of introducing a gene there can also be used, for example, a method involving infection with a viral vector, such as a retrovirus vector, an adenovirus vector, a lentivirus vector, an adeno-associated virus vector, a herpesvirus vector, or a Sendai virus vector; and in the case of introduction of a gene and an expression product thereof, a method involving transfection with a plasmid vector, an episomal vector, or a gene expression product (mRNA, protein) by a non-viral vector, such as a cationic liposome, a cationic polymer, or electroporation.
- mRNA can also be introduced.
- all of the means to be used for gene introduction are collectively referred to as "vector”.
- a virus vector is preferable, and plasmid is preferable to suppress the risk of canceration.
- a drug selective marker Conferring resistance to puromycin, blasticidin S, neomycin, hygromycin, etc.
- cells that express the object gene can be selected and then used.
- Introduction of gene in the present invention may be performed using a plasmid or a virus vector, for example, retrovirus vector, may also be used. From the aspects of introduction efficiency and stable maintenance of the introduced gene, a virus vector is preferable, and plasmid is preferable to suppress the risk of canceration.
- the gene introduced into somatic cells can be transcribed by an LTR promoter, or may be expressed from another promoter in a vector.
- constitutive expression promoters such as CMV promoter, EF-1 ⁇ promoter, and CAG promoter, or desired inductive promoters may be used.
- a chimeric promoter obtained by replacing a portion of LTR with another promoter may also be used.
- a peptide called "protein transduction domain (PTD)" and the like may be bonded to a protein obtained as an expression product, and added to a medium to introduce the peptide into somatic cells.
- PTD protein transduction domain
- differentiated somatic cells of mammals can be cultured in a medium after gene introduction.
- a medium after gene introduction For example, it is a preferable embodiment when inducing (generating) skeletal muscle cell in vitro.
- the culture can be performed in an appropriate container for containing the cells and medium.
- a preferred example of the technique of performing the culture is, but is not limited to, a technique of performing the culture at about 37°C at a carbon dioxide concentration of about 5%.
- the culture under such conditions can be performed by using, for example, a known CO 2 incubator.
- the culture period is not particularly limited as long as the effect of the present invention is not impaired. For example, it can be set to about 12 hours to one month, about one day to 3 weeks, about 3 days to 2 weeks. Where necessary, the medium may be exchanged.
- the culture conditions preferably follow those of a conventional method.
- passage can be performed as necessary.
- the cells are collected before or immediately after the cells reach confluence, and the cells are seeded in fresh medium.
- the medium can be appropriately replaced.
- the medium used in the method of the present invention is not particularly limited.
- Usual liquid media such as DMEM (Dulbecco's Modified Eagle's Medium), EMEM (Eagle's Minimal Essential Medium), ⁇ MEM (alpha Modified Minimum Essential Medium) and the like can be used.
- serum components Fetal Bovine Serum (FBS), Human Serum (HS)
- antibacterial agents such as streptomycin and penicillin, non-essential amino acids (NEAA), and like components can be added.
- a growth factor such as IGF-1 or the like.
- the “differentiation-inducing medium for inducing skeletal muscle cells” refers to a medium containing components that allow pluripotent stem cells (such as ES cells or iPS cells) to differentiate into skeletal muscle cells.
- the differentiation-inducing medium for differentiation of skeletal muscle cells is not particularly limited. Examples thereof include, but are not limited to, a medium for myoblast differentiation ( ⁇ MEM medium added with 1% Non-Essential Amino Acids (NEAA) and 5% Horse Serum and supplemented with IGF-1 10 ng/ml, 100 U/mL Penicillin and 100 ⁇ g/ml Streptomycin).
- ⁇ MEM medium added with 1% Non-Essential Amino Acids (NEAA) and 5% Horse Serum and supplemented with IGF-1 10 ng/ml, 100 U/mL Penicillin and 100 ⁇ g/ml Streptomycin).
- a skeletal muscle cell is induced from a somatic cell.
- the induced skeletal muscle cell contains exogenous MyoD family gene and Myc family gene.
- exogenous means an embodiment of a gene or an expression product thereof that is introduced mainly by the above introduction means and that is different from native embodiment. Examples of the embodiment include genes whose expression is controlled by a promoter other than native promoters, genes present at non-native chromosomal loci, extrachromosomal genes, and the like.
- the skeletal muscle cell may be obtained as a mixture with a cell other than skeletal muscle cell (e.g., original somatic cell).
- the skeletal muscle cell can be separated from the cell other than skeletal muscle cell as necessary.
- the means for separation is not particularly limited. For example, they can be separated using a cell sorter or magnetic beads.
- the skeletal muscle cell induced by the present invention can be preferably used as, for example, the below-mentioned transplantation material.
- the skeletal muscle cell induced by the present invention can also be used for, for example, various studies and development of technologies using skeletal muscle cells.
- the present invention is useful for basic studies such as analysis of the development of skeletal muscle, differentiation, mechanisms of morphogenesis, mechanical stress against these factors, and influences of nutrients and hormones.
- the use of the skeletal muscle cell induced by the present invention allows skeletal muscle cells to be established from humans or animals having various diseases or genetic backgrounds in a simple, rapid, and inexpensive manner. Accordingly, abnormalities in skeletal muscle cells related to the diseases or genetic backgrounds can be analyzed by, for example, a biochemical, molecular biological, or immunological technique. This can contribute to studies on clarification of pathogenic mechanisms of diseases and the like, or development of diagnostic methods. Development of drugs, toxicity tests of drugs, and the like using such skeletal muscle cells can contribute to the development of novel treatment methods for various diseases.
- the skeletal muscle cell induced by the present invention can be used for treating various diseases.
- the skeletal muscle cell may be provided in the form of a transplantation material.
- the transplantation material refers to a skeletal muscle-containing material to be introduced into a living body for repair and reconstruction of muscular tissue (particularly, myofiber).
- the skeletal muscle cells obtained in the present invention can be used for preparation of the transplantation material.
- the skeletal muscle cells themselves can also be used as the transplantation material. Accordingly, the skeletal muscle cells can be transplanted to a patient as a cell preparation, can be transplanted together with a base (scaffold (e.g., amniotic membrane, biocompatible polymer and the like)) formed of an artificial material, or can be cultured with a scaffold, and then transplanted.
- a base sinaffold (e.g., amniotic membrane, biocompatible polymer and the like)
- the target diseases of the above-mentioned treatment include diseases based on defects or lack of skeletal muscle cells such as muscle damage due to trauma or injury, sarcopenia, congenital diaphragmatic hernia, omphalocele, gastroschisis, umbilical hernia, abdominal wall scar hernia after abdominal surgery and the like; diseases based on reduced skeletal muscle function such as prune belly syndrome, Polish syndrome, anorectal malformation (anal atresia), inguinal hernia, disuse syndrome after long-term bed rest and the like; inflammatory myopathies such as dermatomyositis/polymyositis, sporadic inclusion body myositis, myositis associated with viral infection, myositis associated with mycoplasma infection, and the like; metabolic myopathies such as glycogenosis type II (Pompe disease), glycogenosis type III, glycogenosis type V (McArdle disease), glycogenos
- treatment refers to management for a patient suffering from a specific disease or disorder, and means to ameliorate the severity of the disease or disorder, ameliorate one or more symptoms thereof, or delay or reduce the speed of progress of the disease or disorder.
- treatment includes “prevention”.
- the skeletal muscle cell obtained in the present invention may be used not only for treatment of a disease, but also for beauty or functional enhancement.
- management for humans is also referred to as treatment in this specification, the term “patient” can be replaced by the term “healthy subject” or “human,” and the term “disease” can be replaced by the term “beauty” or "function”.
- the present invention can also be used not only for treatment for diseases of humans, but also for treatment for diseases of mammals including pets, such as dogs and cats; and livestock, such as cattle, horses, swine, sheep, and chickens.
- livestock such as cattle, horses, swine, sheep, and chickens.
- the term "patient” is replaced by the term "affected livestock" or "mammal”.
- a skeletal muscle cell can be induced by introducing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into a somatic cell. Therefore, the present invention further provides a composition containing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof for inducing skeletal muscle cells.
- the composition for inducing a skeletal muscle cell contains factor(s) used for inducing a skeletal muscle cell from a somatic cell, in which MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof are desirably contained in a form permitting introduction into a somatic cell.
- the above-mentioned form permitting introduction of genes into a somatic cell is specifically, for example, a vector incorporating the above-mentioned genes.
- the above-mentioned genes may be incorporated in different vectors, or two or more kinds of genes may be simultaneously incorporated in a single vector.
- composition can be used, for example, as a medicament (therapeutic drug) in gene therapy.
- composition of the present invention can be preferably used for the introduction of MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof.
- the induction method of the present invention is appreciated to include the above-mentioned direct ⁇ eprogramming in vivo in addition to direct ⁇ reprogramming in vitro.
- Such direct ⁇ reprogramming in vivo makes it possible to perform, for example, gene therapy to treat various diseases.
- Specific examples of the disease include those described above.
- Direct ⁇ reprogramming in vivo can be performed according to, in addition to the introduction of MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into fibroblasts at the site of damaged skeletal muscle, for example, direct ⁇ reprogramming in vivo into cardiac muscle cells described in the following documents.
- HDF Human Dermal Fibroblast.
- Fig. 1 shows the outline of the method.
- cDNA coding sequences of MyoD1, L-Myc, c-Myc, Oct4, Klf4, and SOX2 genes were incorporated into a retrovirus vector plasmid pMXs.puro by using GeneArt Seamless Cloning & Assembly Kit (Thermo Fisher Scientific).
- Packaging cells, Plat GP cells were suspended in DMEM medium (normal medium) added with 1% NEAA, 10% FBS and supplemented with 100U/mL Penicillin and 100 ⁇ g/ml Streptomycin, and seeded in a gelatin-coated 10 cm culture dish at 5 ⁇ 10 6 cells.
- the pMXs vector incorporating the above-mentioned genes was introduced at the following ratio in various combinations together with pCMV VSV vector by using X-tremeGENE 9.
- transgene 5 ⁇ g, pCMV.VSV 2.5 ⁇ g, Opti-MEM 500 ⁇ l, X-tremeGENE 9 22.5 ⁇ l was added to the 10 cm dish containing 10 ml of the medium.
- aHDF which is a human normal skin fibroblast strain, was seeded in a 10 cm culture dish at 2.2 ⁇ 10 6 cells/mL.
- Plat GP culture supernatant was passed through a syringe filter with a pore diameter of 0.45 ⁇ m and blended with polybrene (final concentration 4 ⁇ g/mL) (virus solution).
- the culture supernatant of human normal skin fibroblast (aHDF) was removed by suction and the virus solution was added (Day 0).
- the culture supernatant was removed by suction and myoblast differentiation medium ( ⁇ MEM medium added with 1% NEAA, 5% Horse Serum and supplemented with IGF-1 10 ng/ml, 100 U/mL Penicillin and 100 ⁇ g/ml Streptomycin) was added. Thereafter, the culture medium was exchanged once every two days and the cells were cultured up to Day 14.
- myoblast differentiation medium ⁇ MEM medium added with 1% NEAA, 5% Horse Serum and supplemented with IGF-1 10 ng/ml, 100 U/mL Penicillin and 100 ⁇ g/ml Streptomycin
- aHDF Human normal skin fibroblasts
- Human MyoD1 gene, human Oct4 gene, human Sox2 gene, human Klf gene, human L-myc gene, human c-Myc gene were introduced in the indicated combinations.
- CKM gene and ⁇ actin gene To quantify mRNA levels of Myogenin gene, CKM gene and ⁇ actin gene, Real-time PCR Master Mix, Taqman pobe, Specific Primer and cDNA were blended and Real-time RT-PCR was performed using AB7300 Real-time PCR system. The value of Myogenin mRNA and CKM mRNA level to ⁇ actin mRNA level in each cell was calculated.
- Fig. 2 The results are shown in Fig. 2 .
- the cell introduced with two genes of MyoD1 and L-Myc showed the most powerful expression of Myogenin gene and CKM gene, which are skeletal muscle cell-specific markers, at the gene level as compared with the control.
- Only the group introduced with both genes of human MyoD1 gene and human L-myc gene showed expression equivalent to that of primary human skeletal muscle cell (pSKM).
- skeletal muscle cell specific markers Myogenin, CKM, Dystrophin
- Human normal skin fibroblast aHDF was cultured in a 12 well plate and subjected to an experiment as in Fig. 1 .
- the culture medium was removed by suction from each well, and the cells were washed with PBS(-).
- the cells were washed three times with PBS(-), after which Blocking One was added and the mixture was incubated at room temperature for 60 min.
- the cell introduced with MyoD1 and LMyc was stained more strongly by CKM, DMD, Myogenin than in primary human myoblast.
- Multinucleated myotube cells were highly frequently observed in the group after co-transfection with MyoD1 and L-Myc. It is clear that cell fusion is promoted by co-transfection of L-Myc or c-Myc gene with MyoD1 gene.
- Human normal skin fibroblast aHDF was cultured in a 12 well plate and cultured according to the method of Fig. 1 . At 14 days after gene transfer, the culture medium was removed by suction from each well, and the cells were washed with PBS(-). After fixing with 4% paraformaldehyde, the cells were washed three times with PBS(-), and nuclear staining was performed using SlowFadeGold anti fade reagent with DAPI manufactured by Life Technologies. The cells were observed under a phase contrast microscope and the cells and nuclei were counted.
- aHDF Human normal skin fibroblasts
- Human MyoD1 gene and human L-myc gene were each singly or simultaneously introduced and 14 days later, total RNA was recovered, and cDNA was synthesized using Rever Tra Ace qPCR RT Master Mix.
- CKM gene, MHC3 gene and ⁇ actin gene To quantify mRNA levels of Myogenin gene, CKM gene, MHC3 gene and ⁇ actin gene, Real-time PCR Master Mix, Taqman pobe, Specific Primer and cDNA were blended and Real-time RT-PCR was performed using AB7300 Real-time PCR system. The values of Myogenin mRNA and CKM mRNA levels to ⁇ actin mRNA level in each cell were calculated.
- the results are shown in Fig. 6 .
- the cell introduced with two genes of MyoD1 and L-Myc showed, as compared with the control, powerful expression of Myogenin gene, CKM gene and MHC3 gene, which are skeletal muscle cell-specific markers, at the gene level which was equivalent to that of primary skeletal muscle cell (pSKM).
- aHDF Human normal skin fibroblasts
- Real-time PCR Master Mix Taqman pobe, Specific Primer and cDNA were blended and Real-time RT-PCR was performed using AB7300 Real-time PCR system. The value of DMD mRNA level to ⁇ actin mRNA level in each cell was calculated.
- Fig. 7 The results are shown in Fig. 7 .
- the cell introduced with two genes of MyoD1 and L-Myc showed expression of DMD gene, which is a protein essential for the functional expression of skeletal muscle cells, wherein the expression became stronger over time to be equivalent to that of primary skeletal muscle cells (pSKM) on day 14.
- DMD gene which is a protein essential for the functional expression of skeletal muscle cells, wherein the expression became stronger over time to be equivalent to that of primary skeletal muscle cells (pSKM) on day 14.
- Fig. 8 shows the outline of the method.
- cDNA coding sequences of MyoD1 and L-Myc genes were incorporated into a retrovirus vector plasmid pMXs.puro by using GeneArt Seamless Cloning & Assembly Kit (Thermo Fisher Scientific).
- Packaging cells, Plat GP cells were suspended in DMEM medium (normal medium) added with 1% NEAA 10% FBS and supplemented with 100 U/mL Penicillin and 100 ⁇ g/ml Streptomycin, and seeded in a gelatin-coated 10 cm culture dish at 5 ⁇ 10 6 cells.
- the pMXs vector containing the above-mentioned genes was introduced at the following ratio in various combinations together with pCMV VSV vector by using X-tremeGENE 9.
- transgene 5 ⁇ g, pCMV.VSV 2.5 ⁇ g, Opti-MEM 500 ⁇ l, X-tremeGENE 9 22.5 ⁇ l was added to the 10 cm dish containing 10 ml of the medium.
- aHDF which is a human normal skin fibroblast strain, was seeded in a 10 cm culture dish at 2.2 ⁇ 10 6 cells/mL.
- Plat GP culture supernatant was passed through a syringe filter with a pore diameter of 0.45 ⁇ m and blended with polybrene (final concentration 4 ⁇ g/mL) (virus solution).
- the culture supernatant of aHDF was removed by suction and the virus solution was added (Day 0).
- the culture supernatant was removed by suction and myoblast differentiation medium ( ⁇ MEM medium added with 1% NEAA, 5% Horse Serum and supplemented with IGF-1 10 ng/ml, 100 U/mL Penicillin and 100 ⁇ g/ml Streptomycin) was added. Thereafter, the culture medium was exchanged once every two days and the cells were cultured up to Day 7.
- myoblast differentiation medium ⁇ MEM medium added with 1% NEAA, 5% Horse Serum and supplemented with IGF-1 10 ng/ml, 100 U/mL Penicillin and 100 ⁇ g/ml Streptomycin
- the cell solution suspended in Matrigel was subcutaneously transplanted into the right upper abdomen of the NOD/SCID mouse by injection.
- aHDF dissolved in 100 ⁇ L of Matrigel (CORNING REF354234) stock solution on ice by 3x10 5 cells was transplanted by injection.
- the mice were euthanized, the upper abdominal skin was detached, and the subcutaneous transplanted tissue was removed together with the skin.
- FIG. 8B Macroscopic images of the transplantation site and the excised tissue one week after transplantation are shown in Fig. 8B . Fibrous nodular tissue was observed at the transplantation site of the cells introduced with MyoD1 and L-Myc genes.
- Example 8 The tissue excised in Example 8 was fixed with 4% paraformaldehyde for 24 hr. Thereafter, embedded in paraffin over 24 hr to prepare a paraffin block.
- a slice section with 3 ⁇ m thickness was produced from the paraffin-fixed mouse subcutaneous tissue specimen.
- the section was incubated at 60°C for 15 min and immersed in xylene for 5 min. This was repeated 3 times. It was further immersed in 100% ethanol for 3 min and this was repeated 3 times. Thereafter, the section was deparaffinized and washed with distilled water for 5 min.
- BLOXALL was added dropwise to cover the section and the section was stood for 10 min at room temperature.
- the slide was lightly knocked against a paper towel to remove serum.
- Desmin antibody, anti-CKM antibody, anti-Dystrophin antibody, anti-ACTA antibody or anti-Myogenin antibody was added dropwise to cover the section.
- the section was stood for 30 min at room temperature and washed with PBS for 5 min.
- the slide was lightly knocked against a paper towel to remove PBS.
- ImmPRESS reagent was added dropwise to cover the section. The section was stood for 30 min and washed with PBS for 5 min, and the washing was performed twice. The slide was lightly knocked against a paper towel to remove PBS.
- ImmPACT DAB Diluent (1 ml) was charged, one drop of ImmPACT DAB Chromogen Concentrate was added and they were mixed well in a Vortex. An enzyme substrate solution was added dropwise to cover the section, and the section was stood for 30 min to 1 min and washed with distilled water for 5 min.
- the section was further washed twice with distilled water for 5 min, and nuclear staining was performed with hematoxylin for 5 min. After washing for 5 min with running water, the section was immersed in a water bath at 50°C for 2 min and washed with running water for 2 min. Immersion in 100% ethanol for 3 min was performed 3 times, and immersion in xylene for 5 min was performed 3 times for dehydration. An encapsulation agent was added dropwise to cover the section and the section was covered with cover glass.
- the tissue was observed with Keyence BZ710 in a bright field.
- a myofiber-like structure was not observed in the subcutaneous tissue, a multinucleated cell was not observed, and a Desmin-positive cell was not observed ( Fig. 9-1 ).
- a myofiber-like structure was observed in the subcutaneous tissue, in which many Desmin positive, CKM positive, ACTA positive multinucleated cells could be confirmed ( Fig. 9-2 ). From these results, it could be confirmed that a cell induced by MyoD1 and L-myc gene is engrafted in vivo after transplantation and forms a myofiber-like tissue.
- human fibroblasts without gene transfer or cells infected with a retrovirus vector incorporating MyoD1 gene and a retrovirus vector incorporating L-myc gene and cultured for 7 days (dMBs (directly converted myoblasts)) were mixed with Matrigel (BD Bioscience, San Jose, CA) at a volume ratio of 1:1, and transplanted into the side abdomen of NOG/SCID mouse (cell number was 3 - 5x10 5 cells/mouse). Seven days later, a tissue at the transplantation site was isolated and, in the same manner as in Example 9, fixed with 4% paraformaldehyde for 8 h, embedded in paraffin and sliced. Immunohistochemistry was performed using anti-desmin antibody, observed under a fluorescence microscope (Keyence BZ710) at x400 magnification, and the percentage of desmin positive cells per one field was calculated.
- Example 2 human fibroblasts were infected with a retrovirus vector incorporating MyoD1 gene (M). Other cells were infected with both retrovirus vector incorporating L-myc gene (L) and retrovirus vector incorporating MyoD1 gene (M) (ML). As a control, cells free of infection with a retrovirus vector were also prepared (-). These were cultured in a myoblast differentiation medium in the same manner as in Example 1. 14 days after infection, immunofluorescent staining using anti-CKM antibody and nuclear staining were performed in the same manner as in Example 3. Images were taken using a fluorescence microscope (Keyence BZ710), and the percentage of CKM positive cells to the total cell number was counted.
- M L-myc gene
- M MyoD1 gene
- Example 12 human fibroblasts were infected with both a retrovirus vector incorporating MyoD1 gene and a retrovirus vector incorporating L-myc gene (ML). As a control, cells free of infection with a retrovirus vector were also prepared (-). A ERK5 pathway inhibitor, XMD8-92, was added at the indicated concentration to some groups. These were cultured in a myoblast differentiation medium in the same manner as in Example 12. 14 days after infection, nuclear staining was performed in the same manner as in Example 3. Images taken using a fluorescence microscope (Keyence BZ710) are shown ( Fig. 13A , upper panel). In addition, the percentages of cells having 4 or more nuclei, cells having 2 - 3 nuclei and cells having one nucleus were calculated ( Fig. 13A , lower panel).
- the fibroblasts without gene transfer were all mononuclear cells, about 40% of the cells infected with ML were cells having not less than 4 nuclei, and about 16% were cells having 2 - 3 nuclei.
- the induction of expression of these myoblast specific genes by ML gene transfer was not suppressed by the addition of XMD8-92. Therefore, it was found that suppression of multinucleation by ERK5 pathway inhibition is not suppression of conversion to myoblasts.
- tissue sections of the transplantation site were subjected to immunohistochemistry respectively using anti-CKM antibody and anti- ⁇ actin antibody by a method similar to that in Example 10.
- human fibroblasts were infected with both a retrovirus vector incorporating MyoD1 gene and a retrovirus vector incorporating L-myc gene (ML) and cultured for 10 days in a myoblast differentiation medium.
- human fibroblasts free of gene transfer were also used (-).
- human fibroblasts were infected with a retrovirus vector incorporating MyoD1 gene (M), retrovirus vector incorporating L-myc (L) and retrovirus vector incorporating c-Myc (C) in the combinations of M alone, MC and ML indicated in the Figure.
- M MyoD1 gene
- L L-myc
- C c-Myc
- cells free of infection with a retrovirus vector were also prepared (-). These were cultured in a myoblast differentiation medium in the same manner as in Example 1. 14 days after infection, the cells were stained with 200 nM MitoTracker Red probe (Invitrogen) at 37°C for 15 min. Images were taken using a fluorescence microscope (Keyence BZ710).
- the results are shown in Fig. 16 .
- the upper photographs show phase difference images and the lower photographs are fluorescence images.
- the cells co-introduced with MC had many mitochondria compared with human fibroblast without gene transfer and the cells introduced with MyoD1 gene alone, and the cells cointroduced with ML had even more mitochondria.
- Human fibroblasts were infected with both a retrovirus vector incorporating MyoD1 gene and a retrovirus vector incorporating L-myc gene and cultured for 6 days.(ML) As a control, human fibroblasts free of gene transfer were also used (-). Immunostaining with anti-desmin antibody or anti-CKM antibody and nuclear staining with DAPI were performed as described.
- ML-introduced cells express myoblast-specific genes Desmin and CKM even after a comparatively short period of culture of 6 days after gene transfer.
- human fibroblasts were infected with a retrovirus vector incorporating MyoD1 gene (M). They were also infected with both retrovirus vector incorporating L-myc gene (L) and retrovirus vector incorporating MyoD1 gene (ML). These were cultured in a myoblast differentiation medium and RNA was extracted from each cell on day 14 after infection. As a control, RNA was also extracted from the cells (-) without infection with retrovirus vector and primary human skeletal muscle cells (pSKMS). These RNAs were subjected to DNA microarray analysis using GeneChip human Gene 1.0 ST (Affymetrix).
- the heatmap and clustering analysis results of each of the gene group involved in the development of skeletal muscle ( Fig. 18A ), the gene group involved in the contraction of skeletal muscle ( Fig. 18B ), the gene group relating to myosin filament ( Fig. 18C ), and the gene group relating to actin filament ( Fig. 18D ) are shown.
- the expression of all these gene groups relating to skeletal muscle in ML-introduced cells showed the highest homology with pSKMS and low homology with fibroblasts.
- M single-introduced cells showed higher homology to fibroblasts than to pSKMS.
- human fibroblasts were infected with both a retrovirus vector incorporating MyoD1 gene and a retrovirus vector incorporating L-myc gene (ML) and cultured in a myoblast differentiation medium.
- the cells were stained with rBC2LCN-FITC (Wako 180-02991) every two days after infection, and the nucleus was stained with Hoechst33342.
- rBC2LCN-FITC Wired Cell-FITC
- the cells before infection with a retrovirus vector leftmost
- human iPS cells hiPS235G1 were also stained similarly. Images of these cells were taken using a fluorescence microscope (Keyence BZ710).
- Fig. 19 The results are shown in Fig. 19 .
- the upper photographs show phase difference images and the lower photographs are fluorescence images.
- Fibroblasts are not stained with rBC2LCN-FITC even when infected with ML. It is clear that conversion of fibroblasts to myoblasts by ML gene introduction does not go through iPS cell-like stem cells.
- MyoD1 gene and L-myc gene were respectively introduced into plasmid vector pCX to construct expression vectors.
- MyoD1 plasmid alone, or both MyoD1 plasmid and L-Myc plasmid were introduced into human fibroblasts (HDFs) by electroporation, and cultured in a myoblast differentiation medium for 14 days.
- RNA was extracted from these cells, and fibroblasts (HDF) without gene transfer as a control, and mRNA of Myogenin gene and CKM gene was quantified by real time RT-PCR. The results are shown in Fig. 19 .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
Abstract
Description
- The present invention mainly relates to a skeletal muscle cell and an induction method thereof. More particularly, it relates to a method for inducing a skeletal muscle cell by direct reprogramming.
- Muscle is an essential tissue for animal exercise and is composed of filamentous multinucleated cells having contractile activity. In induction of differentiation of skeletal muscle, mononuclear myoblasts are differentiated and fused to form multinucleated muscle cells. It is known that differentiation induction of skeletal muscle is controlled by transcription factors such as MyoD family and MEF2 family.
- If muscles can be regenerated and transplanted in diseases such as congenital abnormalities of muscles such as diaphragmatic agenesis and the like, hereditary diseases of muscles such as muscular dystrophy and the like, muscle defects caused by severe trauma or surgical treatment, and the like, it may become an effective new regenerative medicine.
- It has long been known that myoblast-like cells can be induced by introducing a skeletal muscle-specific transcription factor, a gene of the MyoD family, into mouse fibroblasts. However, in human fibroblasts, there is a problem that even if a gene of MyoD family is introduced, myoblasts cannot be induced to the same extent as mouse.
- non-patent document 1: Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell. 1987 Dec 24; 51(6):987-1000.
- The present invention aims to provide a method for inducing skeletal muscle cells that can be applied to a treatment of a disease accompanying muscle defect and the like.
- The present inventors have found that skeletal muscle cells can be obtained directly by introducing MyoD gene and L-myc gene in combination into somatic cells of a mammal (direct reprogramming) without conversion into pluripotent stem cells, such as ES cells and iPS cells. The present invention has been completed by performing further studies based on such findings.
- The present invention encompasses the following invention.
- A method for inducing (generating) a skeletal muscle cell, comprising a step of introducing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into a somatic cell of a mammal.
- The method of
item 1, wherein the aforementioned somatic cell is a fibroblast. - The method of
item 1, wherein the aforementioned somatic cell is a somatic cell of human. - The method of
item - A skeletal muscle cell derived from a somatic cell of a mammal and having exogenous MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof.
- The skeletal muscle cell of
claim 5, which is obtained by the method of any one ofitems 1 to 4. - A transplantation material comprising a cell obtained by the method of any one of
items 1 to 4 or the skeletal muscle cell ofitem 4 for the treatment of a disease based on defect, deficiency or loss of function of skeletal muscle. - A composition for inducing (generating) a skeletal muscle cell, comprising MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof.
- According to the present invention, skeletal muscle cells can be prepared from somatic cells by direct reprogramming in a short period of time. The skeletal muscle cells can be induced easily from somatic cells of a person who undergoes transplantation. Accordingly, when skeletal muscle cells are transplanted, problems, such as an immunological rejection response, do not occur. In addition, skeletal muscle cells can be induced directly from somatic cells without conversion into iPS cells or ES cells, and hence problems due to pluripotent stem cells, such as carcinogenesis, can be avoided.
-
-
Fig. 1 shows the outline of an experiment method. -
Fig. 2 shows mRNA expression measurement results of Myogenin gene and CKM gene. -
Fig. 3-1 shows the results of immunofluorescence staining (CKM). -
Fig. 3-2 shows the results of immunofluorescence staining (Dystrophin). -
Fig. 3-3 shows the results of immunofluorescence staining (Myogenin). -
Fig. 4 shows observation results of the emergence of multinucleated myotube cells. -
Fig. 5 shows evaluation results of the emergence of multinucleated myotube cells. -
Fig. 6 shows mRNA expression measurement results of Myogenin gene, CKM gene and MHC3 gene. -
Fig. 7 shows time-course mRNA expression measurement results of DMD gene. -
Fig. 8A shows the outline of the method of Example 8. -
Fig. 8B shows macroscopic images of the transplanted site and excised tissue one week after transplantation. -
Fig. 9-1 shows the results of immunohistochemical staining of tissue transplanted with fibroblasts. Paraffin section, x200 magnification. -
Fig. 9-2 shows the results of immunohistochemical staining of tissue transplanted with MyoD1 and L-Myc. Paraffin section, x200 magnification. -
Fig. 10 shows the measurement results of desmin positive cells. The values are average value ± standard deviation. Each group N=3 mice. *P<0.05 vs non-introduced cells transplantation group. -
Fig. 11 shows the measurement results of CKM positive cells. The values are average value ± standard deviation. Each group N=3 wells. *P<0.05 vs non-introduced cells. -
Fig. 12 (A) shows the results of nuclear staining. (B) shows the measurement results of percentage of the number of cells with more than 3 nuclei to the total number of cells. -
Fig. 13 (A) shows the measurement results of emergence of multinuclear cell. (B) shows the mRNA expression measurement results of Myogenin gene, CKM gene and Dystrophin gene. -
Fig. 14 shows the results of immunohistochemical staining of tissues transplanted with cells. -
Fig. 15 shows the mRNA expression measurement results of various marker genes. The values are average value ± standard deviation. Each group N=3. *P<0.05 vs non-introduced cell. -
Fig. 16 shows the detection results of mitochondria (MitoTracker Red). -
Fig. 17 shows the results of immunofluorescence staining of Desmin and CKM. -
Fig. 18A shows a heatmap and the results of clustering analysis of a gene group involved in the development of skeletal muscle. -
Fig. 18B shows a heatmap and the results of clustering analysis of a gene group involved in the contraction of skeletal muscle. -
Fig. 18C shows a heatmap and the results of clustering analysis of a gene group relating to myosin filament. -
Fig. 18D shows a heatmap and the results of clustering analysis of a gene group relating to actin filament. -
Fig. 19 shows the results of staining of rBC2 LCN-FITC. -
Fig. 20 shows the mRNA expression measurement results of Myogenin gene and CKM gene. - The present invention relates to a method for inducing a skeletal muscle cell by converting a mammalian differentiated somatic cell into a skeletal muscle cell. The term "convert" herein means changing a somatic cell into a target skeletal muscle cell. One preferred embodiment of the method of the present invention provides a method of converting a somatic cell into a skeletal muscle cell without reprogramming of cells, such as production of iPS cells, which is also called "direct reprogramming" or "direct conversion."
- Induction into a skeletal muscle cell can be performed either in vitro or in vivo.
- During the normal process of development of skeletal muscle, myoblasts fuse into multinucleated myotube cells and mature into myofibers. Normal skeletal muscle tissue contains muscle satellite cells capable of functioning as stem cells. In the present specification, myoblast, muscle satellite cell, myotube cell, myotube, myofiber, mature myofiber and the like are collectively referred to as skeletal muscle cell or muscle cell.
- Skeletal muscle refers to muscles other than cardiac muscle and smooth muscle among animal muscles. Of the striated muscle and smooth muscle, skeletal muscle belongs to the striated muscle. Skeletal muscle cells are multinucleated cells, and muscle fiber is produced from many myoblasts.
- Skeletal muscle cell is derived from mesenchymal stem cell. In differentiation in vivo, mesenchymal stem cell is differentiated into myoblast and many myoblasts are fused to form myotube cell.
- Obtainment of skeletal muscle cell can be evaluated based on gene expression and protein expression of skeletal muscle-specific markers such as Myogenin, creatine kinase muscle (CKM), Myosin heavy chain 3 (MHC 3) and the like, and morphological features such as formation of multinucleus and muscle fibers, functions such as contractile activity and the like.
- Any somatic cells derived from mammals can be used. When skeletal muscle cells are transplanted to a living body, somatic cells (autologous cells) derived from a test subject who undergoes transplantation are preferably used to reduce risks of infection, rejection responses, and the like. However, instead of the autologous cells, skeletal muscle cells prepared in advance from somatic cells of other persons or other animals may be used for, for example, transplantation for muscle deficiency or the like. Alternatively, skeletal muscle cells can be prepared from somatic cells of another person or another animal prepared in advance, and used for transplantation. That is, a skeletal muscle cell bank can be prepared in advance, and used for transplantation. In such a case, in order to reduce risks, such as rejection responses, MHC typing can be carried out in advance. Further, cell properties and tumorigenicity of skeletal muscle cells can be confirmed in advance.
- In the present specification, examples of mammals include mice, rats, hamsters, humans, dogs, cats, monkeys, rabbits, cows, horses, pigs, and the like, particularly humans.
- The somatic cell as the subject of the method of the present invention (direct reprogramming) is not particularly limited.
- As the somatic cell, a somatic cell that can be easily collected from a living body can be used. Examples thereof include fibroblasts, keratinocytes, oral mucosal epithelial cells, nasal mucosal epithelial cells, respiratory mucosal epithelial cells, gastric mucosal epithelial cells, intestinal mucosal epithelial cells, vascular endothelial cells, smooth muscle cells, adipocytes, gingival cells (gingival fibroblasts and gingival epithelial cells), dental pulp cells, periodontal ligament cells, bone marrow cells, bone marrow-derived interstitial cells, leukocytes, lymphocytes, conjunctival epithelial cells, and osteoclasts, preferably fibroblasts, keratinocytes, oral mucosal epithelial cells, gingival cells, leukocytes, and lymphocytes. In the present invention, the above-mentioned cell collected from a living body is preferably used.
- In the method of the present invention, MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof are introduced into somatic cells. As used herein, the "expression product" is, for example, mRNA or protein of MyoD family gene or L-myc gene.
- In the method of the present invention, micro RNA, siRNA, shRNA and DNA expressing them can also be used in addition to the MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof. In addition, various proteins can also be used in combination. From the viewpoint of efficiency with which skeletal muscle cells can be obtained and from the viewpoint of convenience, it is preferable to use two genes of MyoD family gene and Myc family gene, for example, two genes alone of MyoD1 gene and L-myc gene.
- MyoD family gene is a group of genes encoding bHLH (basic helix loop helix) type transcription factors involved in the control of differentiation of muscle. Examples of the MyoD family gene include MyoD1, Myf5, myogenin and MRF4. In the present invention, the MyoD family gene is preferably MyoD1 gene.
- Myc family gene also encodes bHLH (basic helix loop helix) type transcription factors. Examples of the Myc family gene include c-myc, N-myc and L-Myc. In the present invention, the Myc family gene is preferably L-Myc.
- All of the above genes are highly conserved in vertebrates. In this specification, they refer to genes including homologues, unless a specific animal name is described. The genes further include genes having functions equivalent to those of wild-type gene products, even when the genes include mutations including polymorphisms.
- For example, cDNA base sequences of human (Homo sapiens) MyoD1 gene and L-myc gene, and amino acid sequences of proteins encoded by these sequences, have been registered at GenBank provided by the National Center for Biotechnology Information (NCBI), under the following accession numbers (it should be understood that when multiple revisions have been registered, each number refers to the latest revision):
- human MyoD1 gene cDNA sequence: NM_002478 (e.g., NM_002478.4),
- human MyoD1 protein amino acid sequence: NP_002469 (e.g., NP_002469.2);
- human L-myc gene cDNA sequence: NM_001033081, NM_001033082, NM_005376 (e.g., NM_001033081.2, NM_001033082.2, NM_005376.4),
- human L-myc protein amino acid sequence: NP_001028253.1, NP_001028254.2, NP_005367.2 (e.g., NP_001028253, NP_001028254, NP_005367).
- The method of the present invention can be performed according to a known direct reprogramming method, except that specific genes are selected. For example, the method can be performed according to the method described in any one of the following documents:
- 1: Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Masaki Ieda, Ji-Dong Fu, Paul Delgado-Olguin, Vasanth Vedantham, Yohei Hayashi, Benoit G. Bruneau, and Deepak Srivastava, Cell, 142: 375-386, 2010.
- 2: Direct conversion of fibroblasts to functional neurons by defined factors. Thomas Vierbuchen, Austin Ostermeier, Zhiping P. Pang, Yuko Kokubu, Thomas C. Sudhof & Marius Wernig, Nature, 463: 1035-1041, 2010
- 3: Induction of human neuronal cells by defined transcription factors. Pang ZP, Yang N, Vierbuchen T, Ostermeier A, Fuentes DR, Yang TQ, Citri A, Sebastiano V, Marro S, Sudhof TC, Wernig M, Nature, 476: 220-223, 2011.
- 4: Generation of hyaline cartilaginous tissue from mouse adult dermal fibroblast culture by defined factors, Kunihiko Hiramatsu, Satoru Sasagawa, Hidetatsu Outani, Kanako Nakagawa, Hideki Yoshikawa, and Noriyuki Tsumaki, Journal of Clinical Investigation, 121: 640-657, 2011.
- 5: Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Pengyu Huang, Zhiying He, Shuyi Ji, Huawang Sun, Dao Xiang, Changcheng Liu, Yiping Hu, XinWang & Lijian Hui, Nature, 475: 386-389, 2011.
- 6: Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Sayaka Sekiya & Atsushi Suzuki, Nature, 475: 390-393, 2011.
- 7: Direct conversion of human fibroblasts into functional osteoblasts by defined factors. Yamamoto K, Kishida T, Sato Y, Nishioka K, Ejima A, Fujiwara H, Kubo T, Yamamoto T, Kanamura N & Mazda O. Proc Natl Acad Sci USA. 112:6152-6157, 2015.
- 8: Reprogrammed Functional Brown Adipocytes Ameliorate Insulin Resistance and Dyslipidemia in Diet-Induced Obesity and .
- 9: Generation of directly converted human osteoblasts that are free of exogenous gene and xenogenic protein. Yamamoto K., Sato Y., Honjo K., Ichioka H., Oseko F., Sowa Y., Yamamoto T., Kanamura N., Kishida T., Mazda O. J Cell Biochem 117:2538-2545, 2016.
- 10:
WO 2014/010746 - The contents of
Documents 1 to 10 are incorporated herein by reference. - Specifically, it is preferable to incorporate the object gene into one or plural expression vectors and introduce the expression vector into target somatic cells to express the gene in the cells.
- As a method of introducing a gene, there can also be used, for example, a method involving infection with a viral vector, such as a retrovirus vector, an adenovirus vector, a lentivirus vector, an adeno-associated virus vector, a herpesvirus vector, or a Sendai virus vector; and in the case of introduction of a gene and an expression product thereof, a method involving transfection with a plasmid vector, an episomal vector, or a gene expression product (mRNA, protein) by a non-viral vector, such as a cationic liposome, a cationic polymer, or electroporation. Alternatively, mRNA can also be introduced. In this description, all of the means to be used for gene introduction are collectively referred to as "vector".
- From the aspects of introduction efficiency and stable maintenance of the introduced gene, a virus vector is preferable, and plasmid is preferable to suppress the risk of canceration.
- By introducing a drug selective marker (conferring resistance to puromycin, blasticidin S, neomycin, hygromycin, etc.) with an object gene and then performing drug selection, cells that express the object gene can be selected and then used.
- Introduction of gene in the present invention may be performed using a plasmid or a virus vector, for example, retrovirus vector, may also be used. From the aspects of introduction efficiency and stable maintenance of the introduced gene, a virus vector is preferable, and plasmid is preferable to suppress the risk of canceration.
- The gene introduced into somatic cells can be transcribed by an LTR promoter, or may be expressed from another promoter in a vector. For example, constitutive expression promoters, such as CMV promoter, EF-1α promoter, and CAG promoter, or desired inductive promoters may be used. Alternatively, a chimeric promoter obtained by replacing a portion of LTR with another promoter may also be used.
- When the factor to be introduced is an expression product of a gene (such as a protein), a peptide called "protein transduction domain (PTD)" and the like may be bonded to a protein obtained as an expression product, and added to a medium to introduce the peptide into somatic cells.
- In the method of the present invention, differentiated somatic cells of mammals can be cultured in a medium after gene introduction. For example, it is a preferable embodiment when inducing (generating) skeletal muscle cell in vitro.
- The culture can be performed in an appropriate container for containing the cells and medium. A preferred example of the technique of performing the culture is, but is not limited to, a technique of performing the culture at about 37°C at a carbon dioxide concentration of about 5%. The culture under such conditions can be performed by using, for example, a known CO2 incubator.
- The culture period is not particularly limited as long as the effect of the present invention is not impaired. For example, it can be set to about 12 hours to one month, about one day to 3 weeks, about 3 days to 2 weeks. Where necessary, the medium may be exchanged. The culture conditions preferably follow those of a conventional method.
- In culture, passage can be performed as necessary. When passage is performed, the cells are collected before or immediately after the cells reach confluence, and the cells are seeded in fresh medium. In the culture of the present invention, the medium can be appropriately replaced.
- The medium used in the method of the present invention is not particularly limited. Usual liquid media such as DMEM (Dulbecco's Modified Eagle's Medium), EMEM (Eagle's Minimal Essential Medium), αMEM (alpha Modified Minimum Essential Medium) and the like can be used. If necessary, serum components (Fetal Bovine Serum (FBS), Human Serum (HS)), antibacterial agents, such as streptomycin and penicillin, non-essential amino acids (NEAA), and like components can be added.
- It is also possible to add a growth factor such as IGF-1 or the like.
- In view of the high efficiency in the generation of skeletal muscle cells by the method of the present invention, the use of a differentiation-inducing medium for differentiation of skeletal muscle cells as a medium is preferable. The "differentiation-inducing medium for inducing skeletal muscle cells" refers to a medium containing components that allow pluripotent stem cells (such as ES cells or iPS cells) to differentiate into skeletal muscle cells.
- The differentiation-inducing medium for differentiation of skeletal muscle cells is not particularly limited. Examples thereof include, but are not limited to, a medium for myoblast differentiation (αMEM medium added with 1% Non-Essential Amino Acids (NEAA) and 5% Horse Serum and supplemented with IGF-1 10 ng/ml, 100 U/mL Penicillin and 100 µg/ml Streptomycin).
- Thus, a skeletal muscle cell is induced from a somatic cell.
- In one embodiment, the induced skeletal muscle cell contains exogenous MyoD family gene and Myc family gene. The term "exogenous" as used herein means an embodiment of a gene or an expression product thereof that is introduced mainly by the above introduction means and that is different from native embodiment. Examples of the embodiment include genes whose expression is controlled by a promoter other than native promoters, genes present at non-native chromosomal loci, extrachromosomal genes, and the like.
- The skeletal muscle cell may be obtained as a mixture with a cell other than skeletal muscle cell (e.g., original somatic cell). In this case, the skeletal muscle cell can be separated from the cell other than skeletal muscle cell as necessary. The means for separation is not particularly limited. For example, they can be separated using a cell sorter or magnetic beads.
- The skeletal muscle cell induced by the present invention can be preferably used as, for example, the below-mentioned transplantation material.
- The skeletal muscle cell induced by the present invention can also be used for, for example, various studies and development of technologies using skeletal muscle cells. For example, the present invention is useful for basic studies such as analysis of the development of skeletal muscle, differentiation, mechanisms of morphogenesis, mechanical stress against these factors, and influences of nutrients and hormones.
- The use of the skeletal muscle cell induced by the present invention allows skeletal muscle cells to be established from humans or animals having various diseases or genetic backgrounds in a simple, rapid, and inexpensive manner. Accordingly, abnormalities in skeletal muscle cells related to the diseases or genetic backgrounds can be analyzed by, for example, a biochemical, molecular biological, or immunological technique. This can contribute to studies on clarification of pathogenic mechanisms of diseases and the like, or development of diagnostic methods. Development of drugs, toxicity tests of drugs, and the like using such skeletal muscle cells can contribute to the development of novel treatment methods for various diseases.
- The skeletal muscle cell induced by the present invention can be used for treating various diseases. In this case, the skeletal muscle cell may be provided in the form of a transplantation material.
- The transplantation material refers to a skeletal muscle-containing material to be introduced into a living body for repair and reconstruction of muscular tissue (particularly, myofiber). The skeletal muscle cells obtained in the present invention can be used for preparation of the transplantation material. The skeletal muscle cells themselves can also be used as the transplantation material. Accordingly, the skeletal muscle cells can be transplanted to a patient as a cell preparation, can be transplanted together with a base (scaffold (e.g., amniotic membrane, biocompatible polymer and the like)) formed of an artificial material, or can be cultured with a scaffold, and then transplanted.
- The target diseases of the above-mentioned treatment include
diseases based on defects or lack of skeletal muscle cells such as muscle damage due to trauma or injury, sarcopenia, congenital diaphragmatic hernia, omphalocele, gastroschisis, umbilical hernia, abdominal wall scar hernia after abdominal surgery and the like;
diseases based on reduced skeletal muscle function such as prune belly syndrome, Polish syndrome, anorectal malformation (anal atresia), inguinal hernia, disuse syndrome after long-term bed rest and the like;
inflammatory myopathies such as dermatomyositis/polymyositis, sporadic inclusion body myositis, myositis associated with viral infection, myositis associated with mycoplasma infection, and the like;
metabolic myopathies such as glycogenosis type II (Pompe disease), glycogenosis type III, glycogenosis type V (McArdle disease), glycogenosis type VII (Tarui disease) and the like; muscular dystrophy, myopathy, myasthenia gravis, congenital myasthenic syndrome, mitochondrial disease, amyotrophic lateral sclerosis (ALS), other muscle diseases
and the like. - In the present specification, unless otherwise specified, the term "treatment" refers to management for a patient suffering from a specific disease or disorder, and means to ameliorate the severity of the disease or disorder, ameliorate one or more symptoms thereof, or delay or reduce the speed of progress of the disease or disorder. In this specification, "treatment" includes "prevention".
- The skeletal muscle cell obtained in the present invention may be used not only for treatment of a disease, but also for beauty or functional enhancement. In such a case, for expediency, management for humans is also referred to as treatment in this specification, the term "patient" can be replaced by the term "healthy subject" or "human," and the term "disease" can be replaced by the term "beauty" or "function".
- The present invention can also be used not only for treatment for diseases of humans, but also for treatment for diseases of mammals including pets, such as dogs and cats; and livestock, such as cattle, horses, swine, sheep, and chickens. In such a case, the term "patient" is replaced by the term "affected livestock" or "mammal".
- As described above, a skeletal muscle cell can be induced by introducing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into a somatic cell. Therefore, the present invention further provides a composition containing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof for inducing skeletal muscle cells. The composition for inducing a skeletal muscle cell contains factor(s) used for inducing a skeletal muscle cell from a somatic cell, in which MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof are desirably contained in a form permitting introduction into a somatic cell. The above-mentioned form permitting introduction of genes into a somatic cell is specifically, for example, a vector incorporating the above-mentioned genes. As used herein, the above-mentioned genes may be incorporated in different vectors, or two or more kinds of genes may be simultaneously incorporated in a single vector.
- The kind and the like of a usable vector are as described above.
- The above-mentioned composition can be used, for example, as a medicament (therapeutic drug) in gene therapy.
- By introducing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into fibroblasts present at a site lacking skeletal muscle and the like, skeletal muscle cells are induced at the damaged site by direct·reprogramming, which in turn can contribute to the treatment of damaged skeletal muscle and regeneration of skeletal muscle. The above-mentioned composition of the present invention can be preferably used for the introduction of MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof.
- The induction method of the present invention is appreciated to include the above-mentioned direct·eprogramming in vivo in addition to direct·reprogramming in vitro. Such direct·reprogramming in vivo makes it possible to perform, for example, gene therapy to treat various diseases. Specific examples of the disease include those described above.
- Direct·reprogramming in vivo can be performed according to, in addition to the introduction of MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into fibroblasts at the site of damaged skeletal muscle, for example, direct·reprogramming in vivo into cardiac muscle cells described in the following documents.
- 1: Ieda M. Heart regeneration using reprogramming technology. Proc Jpn Acad Ser B Phys Biol Sci. 2013; 89(3):118-28. Review.
- 2: Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, Srivastava D. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell. 2010 .
- 3: Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, Liu L, Conway SJ, Fu JD, Srivastava D. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature. 2012 May 31; 485(7400):593-8.
- The contents of the above-mentioned
documents 1 to 3 are incorporated in the present specification by reference. - While the Examples are shown below, the present invention is not limited to the Examples alone.
- In the Examples, HDF refers to Human Dermal Fibroblast.
-
Fig. 1 shows the outline of the method. cDNA coding sequences of MyoD1, L-Myc, c-Myc, Oct4, Klf4, and SOX2 genes were incorporated into a retrovirus vector plasmid pMXs.puro by using GeneArt Seamless Cloning & Assembly Kit (Thermo Fisher Scientific). Packaging cells, Plat GP cells, were suspended in DMEM medium (normal medium) added with 1% NEAA, 10% FBS and supplemented with 100U/mL Penicillin and 100 µg/ml Streptomycin, and seeded in a gelatin-coated 10 cm culture dish at 5×106 cells. - After 24 hr culture, the pMXs vector incorporating the above-mentioned genes was introduced at the following ratio in various combinations together with pCMV VSV vector by using X-tremeGENE 9.
- That is, a blending solution of
transgene 5 µg, pCMV.VSV 2.5 µg, Opti-MEM 500 µl, X-tremeGENE 9 22.5 µl was added to the 10 cm dish containing 10 ml of the medium. - After 24 hours, the medium was changed to a normal medium free of an antibiotic agent. On the same day, aHDF, which is a human normal skin fibroblast strain, was seeded in a 10 cm culture dish at 2.2×106 cells/mL.
- After 24 hours, Plat GP culture supernatant was passed through a syringe filter with a pore diameter of 0.45 µm and blended with polybrene (
final concentration 4 µg/mL) (virus solution). - The culture supernatant of human normal skin fibroblast (aHDF) was removed by suction and the virus solution was added (Day 0).
- After 24 hours of culture and infection, the culture supernatant was removed by suction and myoblast differentiation medium (αMEM medium added with 1% NEAA, 5% Horse Serum and supplemented with IGF-1 10 ng/ml, 100 U/mL Penicillin and 100 µg/ml Streptomycin) was added. Thereafter, the culture medium was exchanged once every two days and the cells were cultured up to
Day 14. - mRNA expression results of Myogenin gene and CKM gene in the conversion of human normal skin fibroblast to myoblast.
- Human normal skin fibroblasts (aHDF) were seeded in a 12 well plate and cultured according to the method of
Fig. 1 . - Human MyoD1 gene, human Oct4 gene, human Sox2 gene, human Klf gene, human L-myc gene, human c-Myc gene were introduced in the indicated combinations.
- At 14 days after gene transfer, total RNA was recovered, and cDNA was synthesized using Rever Tra Ace qPCR RT Master Mix. To quantify mRNA levels of Myogenin gene, CKM gene and β actin gene, Real-time PCR Master Mix, Taqman pobe, Specific Primer and cDNA were blended and Real-time RT-PCR was performed using AB7300 Real-time PCR system. The value of Myogenin mRNA and CKM mRNA level to β actin mRNA level in each cell was calculated.
- The results are shown in
Fig. 2 . The cell introduced with two genes of MyoD1 and L-Myc showed the most powerful expression of Myogenin gene and CKM gene, which are skeletal muscle cell-specific markers, at the gene level as compared with the control. Only the group introduced with both genes of human MyoD1 gene and human L-myc gene showed expression equivalent to that of primary human skeletal muscle cell (pSKM). - Cells were cultured in a 12 well plate and expression of skeletal muscle cell specific markers (Myogenin, CKM, Dystrophin) was confirmed by immunofluorescence staining. Human normal skin fibroblast aHDF was cultured in a 12 well plate and subjected to an experiment as in
Fig. 1 . At 14 days after gene transfer, the culture medium was removed by suction from each well, and the cells were washed with PBS(-). After fixing with 4% paraformaldehyde, the cells were washed three times with PBS(-), after which Blocking One was added and the mixture was incubated at room temperature for 60 min. - Primary antibodies (anti-CKM antibody, anti-Dystrophin antibody, anti-Myogenin antibody) were reacted overnight at 4°C and washed 3 times with Wash buffer. Secondary antibodies (Alexa 488-conjugated anti-rabbit IgG antibody, Alexa 546-conjugated anti-mouse IgG antibody) were reacted at room temperature for 1 hr, washed 3 times with Wash buffer, and nuclear staining was performed using SlowFadeGold anti fade reagent with DAPI manufactured by Life Technologies. Images were taken using a fluorescence microscope (Keyence BZ710).
- The results are shown in
Figs. 3-1 ,3-2 ,3-3 . CKM, DMD, Myogenin were more powerful and more positive in the cell introduced with MyoD1 and LMyc than in the cell introduced with MyoD1 alone. - In addition, the cell introduced with MyoD1 and LMyc was stained more strongly by CKM, DMD, Myogenin than in primary human myoblast.
- Cells were cultured in a 12 well plate and emergence of multinucleated myotube cell was observed. Human normal skin fibroblast aHDF was cultured in a 12 well plate and cultured according to the method of
Fig. 1 . At 14 days after gene transfer, the culture medium was removed by suction from each well, and the cells were washed with PBS(-). After fixing with 4% paraformaldehyde, the cells were washed three times with PBS(-), and nuclear staining was performed using SlowFadeGold anti fade reagent with DAPI manufactured by Life Technologies. Images were taken using a fluorescence microscope (Keyence BZ710). Multinucleated myotube cells were highly frequently observed in the group after co-transfection with MyoD1 and L-Myc. It is clear that cell fusion is promoted by co-transfection of L-Myc or c-Myc gene with MyoD1 gene. - Cells were cultured in a 12 well plate and emergence of multinucleated myotube cell was observed.
- Human normal skin fibroblast aHDF was cultured in a 12 well plate and cultured according to the method of
Fig. 1 . At 14 days after gene transfer, the culture medium was removed by suction from each well, and the cells were washed with PBS(-). After fixing with 4% paraformaldehyde, the cells were washed three times with PBS(-), and nuclear staining was performed using SlowFadeGold anti fade reagent with DAPI manufactured by Life Technologies. The cells were observed under a phase contrast microscope and the cells and nuclei were counted. - The results are shown in
Fig. 5 . Myotube cells having more than 3 (not less than 4) nuclei highly frequently emerged in the group introduced with MyoD1 and L-Myc. - mRNA expression results of Myogenin gene, CKM gene and MHC3 gene in the conversion of human normal skin fibroblast to myoblast.
- Human normal skin fibroblasts (aHDF) were cultured in a 12 well plate and cultured according to the method of
Fig. 1 . - Human MyoD1 gene and human L-myc gene were each singly or simultaneously introduced and 14 days later, total RNA was recovered, and cDNA was synthesized using Rever Tra Ace qPCR RT Master Mix. To quantify mRNA levels of Myogenin gene, CKM gene, MHC3 gene and β actin gene, Real-time PCR Master Mix, Taqman pobe, Specific Primer and cDNA were blended and Real-time RT-PCR was performed using AB7300 Real-time PCR system. The values of Myogenin mRNA and CKM mRNA levels to β actin mRNA level in each cell were calculated.
- The results are shown in
Fig. 6 . The cell introduced with two genes of MyoD1 and L-Myc showed, as compared with the control, powerful expression of Myogenin gene, CKM gene and MHC3 gene, which are skeletal muscle cell-specific markers, at the gene level which was equivalent to that of primary skeletal muscle cell (pSKM). - Time-course mRNA expression results of DMD gene in the conversion of human normal skin fibroblast to myoblast.
- Human normal skin fibroblasts (aHDF) were cultured in a 12 well plate and cultured according to the method of
Fig. 1 . - Human MyoD1 gene and human L-myc gene were co-transfected, and total RNA was recovered on 0, 2, 4, 6, 8, 10, 12, and 14 days after introduction. cDNA was synthesized using Rever Tra Ace qPCR RT Master Mix. To quantify mRNA levels of DMD gene and β actin gene, Real-time PCR Master Mix, Taqman pobe, Specific Primer and cDNA were blended and Real-time RT-PCR was performed using AB7300 Real-time PCR system. The value of DMD mRNA level to β actin mRNA level in each cell was calculated.
- The results are shown in
Fig. 7 . The cell introduced with two genes of MyoD1 and L-Myc showed expression of DMD gene, which is a protein essential for the functional expression of skeletal muscle cells, wherein the expression became stronger over time to be equivalent to that of primary skeletal muscle cells (pSKM) onday 14. - Cells introduced with MyoD1 and L-Myc were cultured for 7 days and subcutaneously transplanted to the abdomen of mouse by injection. A section was produced from an isolated specimen and immunostaining was performed.
-
Fig. 8 shows the outline of the method. cDNA coding sequences of MyoD1 and L-Myc genes were incorporated into a retrovirus vector plasmid pMXs.puro by using GeneArt Seamless Cloning & Assembly Kit (Thermo Fisher Scientific). Packaging cells, Plat GP cells, were suspended in DMEM medium (normal medium) added with 1% NEAA 10% FBS and supplemented with 100 U/mL Penicillin and 100 µg/ml Streptomycin, and seeded in a gelatin-coated 10 cm culture dish at 5×106 cells. - After 24 hr culture, the pMXs vector containing the above-mentioned genes was introduced at the following ratio in various combinations together with pCMV VSV vector by using X-tremeGENE 9.
- That is, a blending solution of
transgene 5 µg, pCMV.VSV 2.5 µg, Opti-MEM 500 µl, X-tremeGENE 9 22.5 µl was added to the 10 cm dish containing 10 ml of the medium. - After 24 hours, the medium was changed to a normal medium free of an antibiotic agent. On the same day, aHDF, which is a human normal skin fibroblast strain, was seeded in a 10 cm culture dish at 2.2×106 cells/mL.
- After 24 hours, Plat GP culture supernatant was passed through a syringe filter with a pore diameter of 0.45 µm and blended with polybrene (
final concentration 4 µg/mL) (virus solution). - The culture supernatant of aHDF was removed by suction and the virus solution was added (Day 0).
- After 24 hours of culture and infection, the culture supernatant was removed by suction and myoblast differentiation medium (αMEM medium added with 1% NEAA, 5% Horse Serum and supplemented with IGF-1 10 ng/ml, 100 U/mL Penicillin and 100 µg/ml Streptomycin) was added. Thereafter, the culture medium was exchanged once every two days and the cells were cultured up to
Day 7. - On
Day 7, the cells were detached from the dish using Accutase and dissolved in 100 µL of Matrigel (CORNING REF354234) stock solution by 3x105 cells on ice. - The cell solution suspended in Matrigel was subcutaneously transplanted into the right upper abdomen of the NOD/SCID mouse by injection. aHDF dissolved in 100 µL of Matrigel (CORNING REF354234) stock solution on ice by 3x105 cells was transplanted by injection. One week after transplantation by injection, the mice were euthanized, the upper abdominal skin was detached, and the subcutaneous transplanted tissue was removed together with the skin.
- Macroscopic images of the transplantation site and the excised tissue one week after transplantation are shown in
Fig. 8B . Fibrous nodular tissue was observed at the transplantation site of the cells introduced with MyoD1 and L-Myc genes. - The tissue excised in Example 8 was fixed with 4% paraformaldehyde for 24 hr. Thereafter, embedded in paraffin over 24 hr to prepare a paraffin block.
- A slice section with 3 µm thickness was produced from the paraffin-fixed mouse subcutaneous tissue specimen. The section was incubated at 60°C for 15 min and immersed in xylene for 5 min. This was repeated 3 times. It was further immersed in 100% ethanol for 3 min and this was repeated 3 times. Thereafter, the section was deparaffinized and washed with distilled water for 5 min.
- Then, BLOXALL was added dropwise to cover the section and the section was stood for 10 min at room temperature.
- After washing with PBS for 5 min, 2.5% horse serum was added dropwise to cover the section and the section was stood for 20 min at room temperature.
- The slide was lightly knocked against a paper towel to remove serum. As a primary antibody, Desmin antibody, anti-CKM antibody, anti-Dystrophin antibody, anti-ACTA antibody or anti-Myogenin antibody was added dropwise to cover the section. The section was stood for 30 min at room temperature and washed with PBS for 5 min. The slide was lightly knocked against a paper towel to remove PBS.
- ImmPRESS reagent was added dropwise to cover the section. The section was stood for 30 min and washed with PBS for 5 min, and the washing was performed twice. The slide was lightly knocked against a paper towel to remove PBS.
- ImmPACT DAB Diluent (1 ml) was charged, one drop of ImmPACT DAB Chromogen Concentrate was added and they were mixed well in a Vortex. An enzyme substrate solution was added dropwise to cover the section, and the section was stood for 30 min to 1 min and washed with distilled water for 5 min.
- The section was further washed twice with distilled water for 5 min, and nuclear staining was performed with hematoxylin for 5 min. After washing for 5 min with running water, the section was immersed in a water bath at 50°C for 2 min and washed with running water for 2 min. Immersion in 100% ethanol for 3 min was performed 3 times, and immersion in xylene for 5 min was performed 3 times for dehydration. An encapsulation agent was added dropwise to cover the section and the section was covered with cover glass.
- The tissue was observed with Keyence BZ710 in a bright field.
- The results are shown in
Fig. 9 . - In the tissue transplanted with fibroblasts, a myofiber-like structure was not observed in the subcutaneous tissue, a multinucleated cell was not observed, and a Desmin-positive cell was not observed (
Fig. 9-1 ). On the other hand, in the tissue transplanted with the cells introduced with MyoD1 and L-Myc, a myofiber-like structure was observed in the subcutaneous tissue, in which many Desmin positive, CKM positive, ACTA positive multinucleated cells could be confirmed (Fig. 9-2 ). From these results, it could be confirmed that a cell induced by MyoD1 and L-myc gene is engrafted in vivo after transplantation and forms a myofiber-like tissue. - In the same manner as in Examples 8 and 9, human fibroblasts (aHDFs) without gene transfer or cells infected with a retrovirus vector incorporating MyoD1 gene and a retrovirus vector incorporating L-myc gene and cultured for 7 days (dMBs (directly converted myoblasts)) were mixed with Matrigel (BD Bioscience, San Jose, CA) at a volume ratio of 1:1, and transplanted into the side abdomen of NOG/SCID mouse (cell number was 3 - 5x105 cells/mouse). Seven days later, a tissue at the transplantation site was isolated and, in the same manner as in Example 9, fixed with 4% paraformaldehyde for 8 h, embedded in paraffin and sliced. Immunohistochemistry was performed using anti-desmin antibody, observed under a fluorescence microscope (Keyence BZ710) at x400 magnification, and the percentage of desmin positive cells per one field was calculated.
- The results are shown in
Fig. 10 . It is clear that a significantly large number of desmin-positive cells were present in the tissue at the transplantation site in the group transplanted with ML-introduced cells (dMBs (directly converted myoblasts)). The values are average value ± standard deviation. Each group N=3 mice. *P<0.05 vs non-introduced cell transplantation group. - In the same manner as in Example 1, human fibroblasts were infected with a retrovirus vector incorporating MyoD1 gene (M). Other cells were infected with both retrovirus vector incorporating L-myc gene (L) and retrovirus vector incorporating MyoD1 gene (M) (ML). As a control, cells free of infection with a retrovirus vector were also prepared (-). These were cultured in a myoblast differentiation medium in the same manner as in Example 1. 14 days after infection, immunofluorescent staining using anti-CKM antibody and nuclear staining were performed in the same manner as in Example 3. Images were taken using a fluorescence microscope (Keyence BZ710), and the percentage of CKM positive cells to the total cell number was counted.
- The results are shown in
Fig. 11 . About 26% of the cells introduced with MyoD1 gene alone were CKM positive, whereas about 90% of the cells co-introduced with MyoD1 gene and L-myc gene were CKM positive. Therefore, it was found that about 90% of human fibroblasts are converted to myoblasts by co-introduction with MyoD1 and L-myc genes. The values are average value ± standard deviation. N=3 wells/group. *P<0.05 vs non-introduced cells. - In the same manner as in Example 1, human fibroblasts were infected with a retrovirus vector incorporating MyoD1 gene (M), retrovirus vector incorporating L-myc gene (L) and retrovirus vector incorporating c-Myc gene (C) in the described combination. As a control, cells free of infection with a retrovirus vector were also prepared (-). These were cultured in a myoblast differentiation medium in the same manner as in Example 1. 14 days after infection, nuclear staining was performed in the same manner as in Example 3. Images were taken using a fluorescence microscope (Keyence BZ710) (
Fig. 12A ). In addition, the percentage of cells having more than 3 nuclei was counted (Fig. 12B ). - About 6% of the cells introduced with MyoD1 gene alone were cells having more than 3 nuclei, whereas about 43% of the cells co-introduced with MyoD1 gene and L-myc gene were cells having more than 3 nuclei. About 27% of the cells co-introduced with MyoD1 gene and c-Myc gene were cells having more than 3 nuclei. Therefore, it was found that the cells co-introduced with MyoD1 gene and L-myc gene become multinucleated cells with the highest efficiency. The values of
Fig. 12B are average value ± standard deviation. Each group N=3 wells. *P<0.05 vs non-introduced cells. - In the same manner as in Example 12, human fibroblasts were infected with both a retrovirus vector incorporating MyoD1 gene and a retrovirus vector incorporating L-myc gene (ML). As a control, cells free of infection with a retrovirus vector were also prepared (-). A ERK5 pathway inhibitor, XMD8-92, was added at the indicated concentration to some groups. These were cultured in a myoblast differentiation medium in the same manner as in Example 12. 14 days after infection, nuclear staining was performed in the same manner as in Example 3. Images taken using a fluorescence microscope (Keyence BZ710) are shown (
Fig. 13A , upper panel). In addition, the percentages of cells having 4 or more nuclei, cells having 2 - 3 nuclei and cells having one nucleus were calculated (Fig. 13A , lower panel). - The fibroblasts without gene transfer were all mononuclear cells, about 40% of the cells infected with ML were cells having not less than 4 nuclei, and about 16% were cells having 2 - 3 nuclei. However, addition of 2 - 5 µM XMD8-92, which is an ERK5 inhibitor, decreased the cells having not less than 4 nuclei to about 10 - 12%, and the cells having 2 - 3 nuclei to about 21 - 23%.
- In addition, 14 days after infection, RNA was extracted from the cells. As a control, RNA was also extracted from the primary human skeletal muscle cells (pSKMs). mRNAs of Myogenin, CKM, Dystrophin were quantified by real time RT-PCR. The results are shown in
Fig. 13B . The induction of expression of these myoblast specific genes by ML gene transfer was not suppressed by the addition of XMD8-92. Therefore, it was found that suppression of multinucleation by ERK5 pathway inhibition is not suppression of conversion to myoblasts. - From these results, it was found that multinucleation of cells by co-introduction with MyoD1 gene and L-myc gene is caused by ERK5 pathway dependent cell fusion.
- After experiments in the same manner as in Examples 8, 9, tissue sections of the transplantation site were subjected to immunohistochemistry respectively using anti-CKM antibody and anti-α actin antibody by a method similar to that in Example 10.
- The results are shown in
Fig. 14 . It is clear that many CKM- and α actin-positive myofiber-like tissues were formed in the transplantation sites in a group transplanted with the cells co-introduced with MyoD1 gene and L-myc gene (dMBs (directly converted myoblasts)). - In the same manner as in Example 1, human fibroblasts were infected with both a retrovirus vector incorporating MyoD1 gene and a retrovirus vector incorporating L-myc gene (ML) and cultured for 10 days in a myoblast differentiation medium. As a control, human fibroblasts free of gene transfer were also used (-). The mRNA expression of UCP1 gene and CIDEA gene, which are brown adipocyte markers, SOX9 gene and aggrecan gene, which are chondrocyte markers, and Runx2 gene and osteocalcin gene, which are osteoblast markers, was measured by real time RT-PCR.
- The results are shown in
Fig. 15 . It is clear that the cells co-introduced with MyoD1 gene and L-myc gene (ML-introduced cells) do not significantly increase expression of any of these mesenchymal cell markers. The values are average value ± standard deviation. Each group N=3. *P<0.05 vs. non-introduced cells. - In the same manner as in Example 1, human fibroblasts were infected with a retrovirus vector incorporating MyoD1 gene (M), retrovirus vector incorporating L-myc (L) and retrovirus vector incorporating c-Myc (C) in the combinations of M alone, MC and ML indicated in the Figure. As a control, cells free of infection with a retrovirus vector were also prepared (-). These were cultured in a myoblast differentiation medium in the same manner as in Example 1. 14 days after infection, the cells were stained with 200 nM MitoTracker Red probe (Invitrogen) at 37°C for 15 min. Images were taken using a fluorescence microscope (Keyence BZ710).
- The results are shown in
Fig. 16 . The upper photographs show phase difference images and the lower photographs are fluorescence images. The cells co-introduced with MC had many mitochondria compared with human fibroblast without gene transfer and the cells introduced with MyoD1 gene alone, and the cells cointroduced with ML had even more mitochondria. - Human fibroblasts were infected with both a retrovirus vector incorporating MyoD1 gene and a retrovirus vector incorporating L-myc gene and cultured for 6 days.(ML) As a control, human fibroblasts free of gene transfer were also used (-). Immunostaining with anti-desmin antibody or anti-CKM antibody and nuclear staining with DAPI were performed as described.
- The results are shown in
Fig. 17 . The upper photographs show phase difference images and the lower photographs are fluorescence images. It is clear that ML-introduced cells express myoblast-specific genes Desmin and CKM even after a comparatively short period of culture of 6 days after gene transfer. - In the same manner as in Example 1, human fibroblasts were infected with a retrovirus vector incorporating MyoD1 gene (M). They were also infected with both retrovirus vector incorporating L-myc gene (L) and retrovirus vector incorporating MyoD1 gene (ML). These were cultured in a myoblast differentiation medium and RNA was extracted from each cell on
day 14 after infection. As a control, RNA was also extracted from the cells (-) without infection with retrovirus vector and primary human skeletal muscle cells (pSKMS). These RNAs were subjected to DNA microarray analysis using GeneChip human Gene 1.0 ST (Affymetrix). - The heatmap and clustering analysis results of each of the gene group involved in the development of skeletal muscle (
Fig. 18A ), the gene group involved in the contraction of skeletal muscle (Fig. 18B ), the gene group relating to myosin filament (Fig. 18C ), and the gene group relating to actin filament (Fig. 18D ) are shown. The expression of all these gene groups relating to skeletal muscle in ML-introduced cells showed the highest homology with pSKMS and low homology with fibroblasts. M single-introduced cells showed higher homology to fibroblasts than to pSKMS. - In the same manner as in Example 1, human fibroblasts were infected with both a retrovirus vector incorporating MyoD1 gene and a retrovirus vector incorporating L-myc gene (ML) and cultured in a myoblast differentiation medium. The cells were stained with rBC2LCN-FITC (Wako 180-02991) every two days after infection, and the nucleus was stained with Hoechst33342. As a control, the cells before infection with a retrovirus vector (leftmost) were similarly stained. As a positive control, human iPS cells (hiPS235G1) were also stained similarly. Images of these cells were taken using a fluorescence microscope (Keyence BZ710).
- The results are shown in
Fig. 19 . The upper photographs show phase difference images and the lower photographs are fluorescence images. Fibroblasts are not stained with rBC2LCN-FITC even when infected with ML. It is clear that conversion of fibroblasts to myoblasts by ML gene introduction does not go through iPS cell-like stem cells. - MyoD1 gene and L-myc gene were respectively introduced into plasmid vector pCX to construct expression vectors. MyoD1 plasmid alone, or both MyoD1 plasmid and L-Myc plasmid, were introduced into human fibroblasts (HDFs) by electroporation, and cultured in a myoblast differentiation medium for 14 days. RNA was extracted from these cells, and fibroblasts (HDF) without gene transfer as a control, and mRNA of Myogenin gene and CKM gene was quantified by real time RT-PCR. The results are shown in
Fig. 19 . - The cells co-introduction with MyoD1 and L-myc genes more strongly expressed Myogenin and CKM genes as compared with the cells introduced with MyoD1 gene alone. Therefore, it was shown that transfection using plasmid vector can also induce conversion of fibroblast to myoblast by MyoD1+L-Myc gene introduction.
Claims (8)
- A method for inducing a skeletal muscle cell, comprising a step of introducing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into a somatic cell of a mammal.
- The method according to claim 1, wherein the somatic cell is a fibroblast.
- The method according to claim 1, wherein the somatic cell is a somatic cell of human.
- The method according to any one of claims 1 to 3, wherein the MyoD family gene is MyoD1 gene and the Myc family gene is L-myc gene.
- A skeletal muscle cell derived from a somatic cell of a mammal and having exogenous MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof.
- The skeletal muscle cell according to claim 5, which is obtained by the method of any one of items 1 to 4.
- A transplantation material comprising a cell obtained by the method according to any one of claims 1 to 4 or the skeletal muscle cell according to claim 5 or 6 for the treatment of a disease based on defect, deficiency or loss of function of skeletal muscle.
- A composition for inducing a skeletal muscle cell, comprising MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016255208 | 2016-12-28 | ||
PCT/JP2017/047305 WO2018124292A1 (en) | 2016-12-28 | 2017-12-28 | Skeletal muscle cells and method for inducing same |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3564362A1 true EP3564362A1 (en) | 2019-11-06 |
EP3564362A4 EP3564362A4 (en) | 2020-07-08 |
Family
ID=62709655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17888624.8A Pending EP3564362A4 (en) | 2016-12-28 | 2017-12-28 | Skeletal muscle cells and method for inducing same |
Country Status (6)
Country | Link |
---|---|
US (1) | US11242541B2 (en) |
EP (1) | EP3564362A4 (en) |
JP (1) | JP7165979B2 (en) |
KR (1) | KR102546749B1 (en) |
CN (1) | CN110291190B (en) |
WO (1) | WO2018124292A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020090836A1 (en) * | 2018-10-30 | 2020-05-07 | 国立大学法人京都大学 | Cell production method |
EP3976069A4 (en) * | 2019-05-31 | 2023-07-19 | Figene, LLC | Fibroblast therapy for treatment of duchenne muscular dystrophy |
JPWO2021039972A1 (en) | 2019-08-30 | 2021-03-04 | ||
KR20220011301A (en) * | 2020-07-21 | 2022-01-28 | 씨제이제일제당 (주) | Method of Inducing Bovine Somatic Cells to Bovine Myogenic Cells |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9419048D0 (en) | 1994-09-20 | 1994-11-09 | Watt Diana J | Treatment of muscular disorders |
JP5896421B2 (en) | 2010-04-22 | 2016-03-30 | 国立大学法人京都大学 | Differentiation induction method from pluripotent stem cells to skeletal muscle or skeletal muscle progenitor cells |
WO2013003475A1 (en) * | 2011-06-27 | 2013-01-03 | Cellscript, Inc. | Inhibition of innate immune response |
US10155929B2 (en) * | 2012-05-13 | 2018-12-18 | Allele Biotechnology & Pharmaceuticals, Inc. | Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA |
WO2014010746A1 (en) | 2012-07-12 | 2014-01-16 | 京都府公立大学法人 | Brown fat cells and method for preparing same |
CA2919324A1 (en) * | 2013-07-26 | 2015-01-29 | Kenta Yamamoto | Osteoblast and method for preparing same |
-
2017
- 2017-12-28 US US16/474,416 patent/US11242541B2/en active Active
- 2017-12-28 WO PCT/JP2017/047305 patent/WO2018124292A1/en unknown
- 2017-12-28 CN CN201780081655.8A patent/CN110291190B/en active Active
- 2017-12-28 EP EP17888624.8A patent/EP3564362A4/en active Pending
- 2017-12-28 KR KR1020197021951A patent/KR102546749B1/en active IP Right Grant
- 2017-12-28 JP JP2018559641A patent/JP7165979B2/en active Active
Non-Patent Citations (5)
Title |
---|
ANDRIANA MARGARITI ET AL: "Direct reprogramming of adult cells: avoiding the pluripotent state", STEM CELLS AND CLONING: ADVANCES AND APPLICATIONS, 1 February 2014 (2014-02-01), pages 19, XP055343462, DOI: 10.2147/SCCAA.S38006 * |
CONACCI-SORRELL MARALICE ET AL: "Myc-Nick: A Cytoplasmic Cleavage Product of Myc that Promotes [alpha]-Tubulin Acetylation and Cell Differentiation", CELL, vol. 142, no. 3, 6 August 2010 (2010-08-06), pages 480 - 493, XP028931199, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2010.06.037 * |
JEFFREY H MINER ET AL: "c-myc Inhibition of MyoD and Myogenin-Initiated Myogenic Differentiation", MOLECULAR AND CELLULAR BIOLOGY, 1 January 1991 (1991-01-01), pages 2842 - 2851, XP055613030, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC360069/pdf/molcellb00139-0518.pdf> [retrieved on 20190814], DOI: 10.1128/MCB.11.5.2842 * |
See also references of WO2018124292A1 * |
WAKAO JUNKO ET AL: "Efficient direct conversion of human fibroblasts into myogenic lineage induced by co-transduction withMYCLandMYOD1", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 488, no. 2, 10 May 2017 (2017-05-10), pages 368 - 373, XP085033865, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2017.05.059 * |
Also Published As
Publication number | Publication date |
---|---|
EP3564362A4 (en) | 2020-07-08 |
US20190338306A1 (en) | 2019-11-07 |
JP7165979B2 (en) | 2022-11-07 |
WO2018124292A1 (en) | 2018-07-05 |
KR20190104354A (en) | 2019-09-09 |
CN110291190A (en) | 2019-09-27 |
JPWO2018124292A1 (en) | 2019-11-07 |
CN110291190B (en) | 2024-06-04 |
KR102546749B1 (en) | 2023-06-22 |
US11242541B2 (en) | 2022-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11242541B2 (en) | Skeletal muscle cells and method for inducing same | |
Volonte et al. | The modulation of caveolin‐1 expression controls satellite cell activation during muscle repair | |
EP2873727B1 (en) | Brown fat cells and method for preparing same | |
EP3196305B1 (en) | Schwann cells and method for preparing same | |
JP2015221038A (en) | Somatic stem cells | |
CN102459576A (en) | Compositions and methods for modulating stem cells and uses thereof | |
Cassano et al. | Alteration of cardiac progenitor cell potency in GRMD dogs | |
WO2004012503A2 (en) | Compositions comprising muscle progenitor cells and uses thereof | |
WO2014141392A1 (en) | Method for producing regular fibrous connective tissue | |
US11021685B2 (en) | Osteoblasts and method for generating same | |
EP4023248A1 (en) | Urothelial cell induction agent and method for inducing urothelial cells | |
Estiri et al. | Therapeutic effects of mesenchymal stem cells expressing erythropoietin on cancer-related anemia in mice model | |
JP2019076008A (en) | Precursor cells capable of differentiating into osteocytes, chondrocytes, adipocytes or neurons, method for producing the same, and method for using the same | |
KR102100490B1 (en) | Gene and Cell therapy using cell fusion technology and use thereof | |
US20220010289A1 (en) | Materials and Methods for Pathologies in Muscle following Injury, Disease or Aging | |
US20110223138A1 (en) | Mesenchymal stem cells that express increased amounts of anti-apoptotic proteins | |
JP2020524515A (en) | Cell reprogramming method for producing chondrocytes | |
XQOLPLWHG | PRINCIPAL INVESTIGATOR | |
CN114286685A (en) | Modified cells and related methods | |
Jiang | Cellular and molecular regulation of skeletal muscle regeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190708 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200609 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 21/00 20060101ALI20200604BHEP Ipc: A61K 35/34 20150101ALI20200604BHEP Ipc: C12N 5/077 20100101AFI20200604BHEP Ipc: C12N 5/10 20060101ALI20200604BHEP Ipc: C12N 15/09 20060101ALI20200604BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220713 |